Skip to main content
. 2024 Dec 15;16:17588359241305091. doi: 10.1177/17588359241305091

Table 1.

Clinical characteristics of the training and validation cohorts.

All (n, %) Training cohort (n, %) Validation cohort (n, %) p Value
N 192 123 69
Age (mean, SD), years 68.9 ± 12.1 69.0 ± 11.5 68.7 ± 13.4 0.54
 Median (range) 70 (63–78) 70 (63–78) 70 (64–79)
Age 0.54
 <60 35 (18.2) 24 (19.5) 11 (15.9)
 ⩾60 157 (81.8) 99 (80.5) 58 (84.1)
Gender 0.47
 Female 79 (41.1) 53 (43.1) 26 (37.7)
 Male 113 (58.9) 70 (56.9) 43 (62.3)
ECOG 0.14
 0–1 154 (80.6) 103 (83.7) 51 (75.0)
 ⩾2 37 (19.4) 20 (16.3) 17 (25.0)
Renal function (mL/min) 0.01
 CCr ⩾ 60 66 (34.9) 50 (41.7) 16 (23.2)
 CCr < 60 123 (65.1) 70 (58.3) 53 (76.8)
Primary site 0.007
 Bladder 86 (44.8) 64 (52.0) 22 (31.9)
 Upper tract 104 (54.2) 59 (48.0) 45 (65.2)
 Both 2(1.0) 0(0) 2(2.9)
Visceral metastasis 0.35
 No 91 (47.6) 55 (45.1) 36 (52.2)
 Yes 100 (52.4) 67 (54.9) 33 (47.8)
Lymph node metastasis 0.96
 No 53 (27.7) 34 (27.9) 19 (27.5)
 Yes 138 (72.3) 88 (72.1) 50 (72.5)
Liver metastasis 0.012
 No 150 (78.5) 89 (73.0) 61 (88.4)
 Yes 41 (21.5) 33 (27.0) 8 (11.6)
Lung metastasis 0.27
 No 126 (66.0) 77 (63.1) 49 (71.0)
 Yes 65 (34.0) 45 (36.9) 20 (29.0)
Bone metastasis 0.68
 No 152 (79.6) 96 (78.7) 56 (81.2)
 Yes 39 (20.4) 26 (21.3) 13 (18.8)
WBC (×103/μL) 0.75
 <10 139 (72.4) 90 (73.2) 49 (71.0)
 ⩾10 53 (27.6) 33 (26.8) 20 (29.0)
NLR 0.81
 <5 108 (56.3) 70 (58.9) 38 (55.1)
 ⩾5 84 (43.8) 53 (43.1) 31 (44.9)
Hemoglobin (g/dL) 0.16
 ⩾10 121 (63.0) 82 (66.7) 39 (56.5)
 <10 71 (37.0) 41 (33.3) 30 (43.5)
Bajorin prognostic factor 0.90
 0 73 (38.2) 47 (38.2) 26 (38.2)
 1 98 (51.3) 64 (52.0) 34 (50.0)
 2 20 (10.5) 12 (9.8) 8 (11.8)
PD-L1 (22C3) 0.08
 <10 72 (37.5) 35 (28.5) 37 (53.6)
 ⩾10 56 (29.2) 36 (29.3) 20 (29.0)
 Missing 64 (33.3) 52 (42.3) 12 (17.4)

CCr, clearance of creatinine; ECOG, Eastern Cooperative Oncology Group; NLR, neutrophil-to-lymphocyte ratio; PD-L1, programmed cell death ligand-1; WBC, white blood cell count.